• Mission

    Spring Bank is devoted to pioneering its revolutionary SMNH chemistry platform to discover and develop a new generation of medicines to improve the lives of patients worldwide.
    About Us
  • Pipeline

    Inarigivir is being developed as a simple, safe and selective oral immunomodulator for inclusion in a combinatorial treatment of hepatitis B.
    Watch Video
  • Science

    Our proprietary small molecule nucleic acid hybrids (SMNH) chemistry platform produces a class of compounds designed to selectively target and modulate the activity of specific proteins implicated in various disease states.
  • Latest News

      • JANUARY 9, 2018

      Spring Bank Strengthens Management Team to Enhance Operations

      Appoints Kevin Leach , Ph.D., as Vice President, Nonclinical & Translational Research Promotes Garrett Winslow to General Counsel HOPKINTON, Mass. , Jan. 09, 2018 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel

      Read more

    See the mechanism of action of inarigivir soproxil, our lead development candidate for the treatment of hepatitis B virus (HBV)